Treatment-related mortality in childhood cancer patients – who, when and how much

Pole JD, Gibson P, Ethier MC, et al. Evaluation of treatment-related mortality among paediatric cancer deaths: a population based analysis. Br J Cancer. 2017 Feb 14;116(4):540–5.

https://doi.org/10.1038/bjc.2016.443 DOI: https://doi.org/10.1038/bjc.2016.443

Gibson P, Pole JD, Lazor T, et al. Treatment-related mortality in newly diagnosed pediatric cancer: a population-based analysis. Cancer Med. 2018 Mar;7(3):707–15.

https://doi.org/10.1002/cam4.1362 DOI: https://doi.org/10.1002/cam4.1362

Loeffen EAH, Knops RRG, Boerhof J, et al. Treatment-related mortality in children with cancer: prevalence and risk factors. Eur J Cancer. 2019 Nov;121:113–22.

https://doi.org/10.1016/j.ejca.2019.08.008 DOI: https://doi.org/10.1016/j.ejca.2019.08.008

Alexander S, Pole JD, Gibson P, et al. Classification of treatment-related mortality in children with cancer: a systematic assessment. Lancet Oncol. 2015 Dec;16(16):e604–10.

https://doi.org/10.1016/S1470-2045(15)00197-7 DOI: https://doi.org/10.1016/S1470-2045(15)00197-7

Danish Chilhood Cancer Registry [Internet]. [cited 01-02-2024]. Available from: https://ugeskriftet.dk/videnskab/dansk-bornecancer-register

Hunger SP, Tran TH, Saha V, et al. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023 Jul;10(7):e510–20.

https://doi.org/10.1016/S2352-3026(23)00088-1 DOI: https://doi.org/10.1016/S2352-3026(23)00088-1

Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021 Mar 2;325(9):833–42.

https://doi.org/10.1001/jama.2021.0669 DOI: https://doi.org/10.1001/jama.2021.0669

Kutny MA, Alonzo TA, Abla O, et al. Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promye-locytic leukemia: a report from the Children’s Oncology Group AAML1331 trial. JAMA Oncol. 2022 Jan 1;8(1):79–87.

https://doi.org/10.1001/jamaoncol.2021.5206 DOI: https://doi.org/10.1001/jamaoncol.2021.5206

Dixon SB, Liu Q, Chow EJ, et al. Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet. 2023 Apr 29;401(10386):1447–57.

https://doi.org/10.1016/S0140-6736(22)02471-0 DOI: https://doi.org/10.1016/S0140-6736(22)02471-0

Armstrong GT, Yasui Y, Robison LL. Reduction in late mortality after childhood cancer. N Engl J Med. 2016 Jul 21;375(3):290–2. https://doi.org/10.1056/NEJMc1604184 DOI: https://doi.org/10.1056/NEJMc1604184

Ehrlich BS, McNeil MJ, Pham LTD, et al. Treatment-related mortality in children with cancer in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Oncol. 2023 Sep;24(9):967–77.

https://doi.org/10.1016/S1470-2045(23)00318-2 DOI: https://doi.org/10.1016/S1470-2045(23)00318-2